Suppr超能文献

皮下脂膜炎样 T 细胞淋巴瘤的遗传特征和临床特征。

Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas.

机构信息

School of Medicine and Health Sciences, College of Medicine, University of Tsukuba, Tsukuba, Japan.

Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.

出版信息

Cancer Sci. 2024 Nov;115(11):3788-3794. doi: 10.1111/cas.16345. Epub 2024 Sep 17.

Abstract

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare peripheral T-cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five-year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole-exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5-year median follow-up, one patient developed autoimmune-related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long-term follow-up.

摘要

皮下脂膜炎样 T 细胞淋巴瘤(SPTCL)是一种罕见的外周 T 细胞淋巴瘤,其特征为皮肤损伤和免疫表现。SPTCL 的五年生存率已超过 80%,提示预后良好。最近的研究揭示了编码免疫调节剂的 HAVCR2 中存在反复出现的种系变异。在这项研究中,我们整合了 36 名 SPTCL 患者的 60 个样本的全外显子组测序数据,其中包括我们队列中的 6 名患者和公开数据中的 30 名患者。我们在 24 名患者的皮肤肿瘤中鉴定出 138 个体细胞突变和 29 名患者中的 23 个 HAVCR2 种系突变。在 6 名日本患者中发现了 4 名 HAVCR2 p.Tyr82Cys 突变。在 4 名患者的临床病程中,所有患者均接受了环磷酰胺、羟基柔红霉素、长春新碱和泼尼松治疗,但所有 4 名患者均未完全缓解。然而,所有患者的病情均保持稳定,接受了包括自体外周血干细胞移植在内的额外治疗。在 7.5 年的中位随访中,1 名患者出现了自身免疫相关疾病,1 名患者发生了其他血液系统恶性肿瘤,导致死亡。据我们所知,这是日本患者中首次报道 HAVCR2 种系突变的复发性,提示需要长期随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f6/11531942/0b40ef5205a8/CAS-115-3788-g004.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验